Four positions in the U.S. cold and flu category that no brand currently answers well. Severity is read from the inside out. The Critical ring carries the most consequential and most defensible position the brand can take.
None of the major U.S. brands carry a bilingual front-of-pack panel or a Latin American pharmaceutical heritage. AXIV's Argentine parent runs thirty years of pharma manufacturing under Savant Pharm. The most defensible position the brand can take.
The consumer who wants a daytime cold medicine strong enough to actually work, without phenylephrine and without the grogginess of NyQuil. Theraflu has moved on phenylephrine. The other mainstream brands have not.
The natural-immune brands own before-you-get-sick. Mainstream OTC owns now-that-you-are-sick. No brand owns the handoff. AXIV's sub-line architecture is the closest fit to claim the continuum.
Mucinex owns mucus in plain terms. The clean-label segment is concentrated at the daily-vitamin end and thin at the active-symptom end. A clean decongestant or expectorant has no current occupant.